Entresto Approval Expands Use to More HF Patients With LVEF Below Normal
The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial.
Diana Ernst, RPh
Editorial Director
Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.
